BC Week In Review | Oct 11, 2010
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (PTO) Board of Appeals and Interferences reversed all previous obviousness rejection claims related to Benitec's U.S. Patent No. 6,573,099. The '099 patent covers the use of DNA...
BC Week In Review | Jun 7, 2010
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (USPTO) Board of Appeals and Interferences will hold an oral hearing Aug. 4 to discuss its U.S. Patent No. 6,573,099. The '099 patent covers the use of...
BC Week In Review | Mar 15, 2010
Company News

Benitec other, infectious news

Benitec said it filed a reply to the U.S. Patent and Trademark Office (USPTO) and requested an oral hearing before the Board of Patent Appeals and Interference regarding claims for U.S. Patent No. 6,573,099. In...
BC Week In Review | Jan 25, 2010
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (USPTO) found four of Benitec's claims for U.S. Patent No. 6,573,099 to be free and allowable. The ruling is the result of Benitec's appeal of a November...
BC Week In Review | May 18, 2009
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (USPTO) withdrew a novelty rejection, to Benitec's U.S. Patent No. 6,573,099. The company said two obviousness claims remain after the November Final Office Action, which rejected the...
BC Week In Review | Apr 20, 2009
Company News

Benitec other, infectious news

Benitec filed a petition with the U.S. Patent and Trademark Office (USPTO) to allow inclusion of additional evidence to support the ongoing reexamination of Benitec's U.S. Patent No. 6,573,099, after the USPTO issued an Advisory...
BC Week In Review | Dec 15, 2008
Company News

Alnylam, Nucleonics, University of California deal

Nucleonics sold its RNAi IP and remaining programs to Alnylam for an undisclosed sum. Nucleonics' most advanced candidate is NUC B1000, a DNA plasmid vector encoding short interfering RNA (siRNA) molecules that target four HBV...
BC Week In Review | Jul 14, 2008
Company News

Alnylam chemistry news

Following initial proceedings, the Opposition Division of the European Patent Office (EPO) overturned the claims of Alnylam’s European Patent No. EP1230375, which covers RNAi technology including inhibiting gene expression with long dsRNA. The ruling follows...
BC Week In Review | Apr 28, 2008
Company News

Benitec, Nucleonics other, infectious news

The U.S. Supreme Court denied Nucleonics' request to review a patent infringement suit brought by Benitec, ending the litigation. Nucleonics had wanted the matter adjudicated, even though the suit was dismissed by the U.S. District...
BC Week In Review | Apr 7, 2008
Company News

Nucleonics management update

Nucleonics Inc. , Horsham, Pa.   Business: Infectious   Hired: Michael Young as CMO, formerly president and managing consultant of MDY-Associates  ...
Items per page:
1 - 10 of 38
BC Week In Review | Oct 11, 2010
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (PTO) Board of Appeals and Interferences reversed all previous obviousness rejection claims related to Benitec's U.S. Patent No. 6,573,099. The '099 patent covers the use of DNA...
BC Week In Review | Jun 7, 2010
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (USPTO) Board of Appeals and Interferences will hold an oral hearing Aug. 4 to discuss its U.S. Patent No. 6,573,099. The '099 patent covers the use of...
BC Week In Review | Mar 15, 2010
Company News

Benitec other, infectious news

Benitec said it filed a reply to the U.S. Patent and Trademark Office (USPTO) and requested an oral hearing before the Board of Patent Appeals and Interference regarding claims for U.S. Patent No. 6,573,099. In...
BC Week In Review | Jan 25, 2010
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (USPTO) found four of Benitec's claims for U.S. Patent No. 6,573,099 to be free and allowable. The ruling is the result of Benitec's appeal of a November...
BC Week In Review | May 18, 2009
Company News

Benitec other, infectious news

Benitec said the U.S. Patent and Trademark Office (USPTO) withdrew a novelty rejection, to Benitec's U.S. Patent No. 6,573,099. The company said two obviousness claims remain after the November Final Office Action, which rejected the...
BC Week In Review | Apr 20, 2009
Company News

Benitec other, infectious news

Benitec filed a petition with the U.S. Patent and Trademark Office (USPTO) to allow inclusion of additional evidence to support the ongoing reexamination of Benitec's U.S. Patent No. 6,573,099, after the USPTO issued an Advisory...
BC Week In Review | Dec 15, 2008
Company News

Alnylam, Nucleonics, University of California deal

Nucleonics sold its RNAi IP and remaining programs to Alnylam for an undisclosed sum. Nucleonics' most advanced candidate is NUC B1000, a DNA plasmid vector encoding short interfering RNA (siRNA) molecules that target four HBV...
BC Week In Review | Jul 14, 2008
Company News

Alnylam chemistry news

Following initial proceedings, the Opposition Division of the European Patent Office (EPO) overturned the claims of Alnylam’s European Patent No. EP1230375, which covers RNAi technology including inhibiting gene expression with long dsRNA. The ruling follows...
BC Week In Review | Apr 28, 2008
Company News

Benitec, Nucleonics other, infectious news

The U.S. Supreme Court denied Nucleonics' request to review a patent infringement suit brought by Benitec, ending the litigation. Nucleonics had wanted the matter adjudicated, even though the suit was dismissed by the U.S. District...
BC Week In Review | Apr 7, 2008
Company News

Nucleonics management update

Nucleonics Inc. , Horsham, Pa.   Business: Infectious   Hired: Michael Young as CMO, formerly president and managing consultant of MDY-Associates  ...
Items per page:
1 - 10 of 38